In the past week, ZVSA stock has gone up by 10.19%, with a monthly gain of 30.59% and a quarterly plunge of -1.78%. The volatility ratio for the week is 6.92%, and the volatility levels for the last 30 days are 6.12% for ZyVersa Therapeutics Inc The simple moving average for the last 20 days is 7.63% for ZVSA stock, with a simple moving average of -42.98% for the last 200 days.
Is It Worth Investing in ZyVersa Therapeutics Inc (NASDAQ: ZVSA) Right Now?
Moreover, the 36-month beta value for ZVSA is 0.78. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ZVSA is 4.76M and currently, short sellers hold a 6.32% of that float. On June 25, 2025, ZVSA’s average trading volume was 3.72M shares.
ZVSA) stock’s latest price update
ZyVersa Therapeutics Inc (NASDAQ: ZVSA) has seen a rise in its stock price by 11918878 in relation to its previous close of 0.66. However, the company has experienced a 10.19% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-25 that WESTON, Fla., June 25, 2025 (GLOBE NEWSWIRE) — ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, announces that it has entered into a share purchase agreement (SPA) with Williamsburg Venture Holdings (WVH), an institutional investor. We anticipate that this partnership will provide a flexible source of funding, enabling the company to progress clinical development of Cholesterol Efflux Mediator™ VAR 200 to treat chronic kidney diseases. The global drug market for kidney diseases was $18 Billion in 2024, with $30 Billion projected by 2034 (Precedence Research).
ZVSA Trading at 11.48% from the 50-Day Moving Average
After a stumble in the market that brought ZVSA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -88.81% of loss for the given period.
Stock Fundamentals for ZVSA
The total capital return value is set at -0.24. Equity return is now at value -91.39, with -41.48 for asset returns.
Currently, EBITDA for the company is -9.14 billion with net debt to EBITDA at 0.75. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.18.
Conclusion
To wrap up, the performance of ZyVersa Therapeutics Inc (ZVSA) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
